Clinical Applications of Positron Emission Tomography in Breast Cancer Patients;Einsatzmöglichkeiten der Positronen-Emissions-Tomographie beim Mammakarzinom

Acta Medica Austriaca

Volumn 24, Issue 2, 1997, Pages 60-62

  Romer W ^a   Avril, N ^a   Schwaiger, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; F 18 Fluorodeoxyglucose; Positron emission tomography

Indexed keywords

BREAST; BREAST TUMOR; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

BLOOD GLUCOSE; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030628941     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with (F-18) 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750.
2. Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, Römer W, Jänicke F, Schwaiger M: Breast imaging with positron emission tomography using F-18 fluorodeoxyglucose: Quantitative image analysis. J Nucl Med 1997, in press.
3. Avril N, Dose J, Jänicke F, Bense S, Ziegler S, Laubenbacher C, Römer W, Pache H, Herz M, Allgayer B, Nathrath W, Graeff H, Schwaiger M: Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-1857.
4. Avril N, Dose J, Jänicke F, Ziegler S, Römer W, Weber W, Herz M, Nathrath W, Graeff H, Schwaiger M: Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204-1209.
5. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR: PET and F-18-FDG in oncology: A clinical update. Nucl Med Biol 1996;23:717-735.
6. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ: PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441-446.
7. DiChiro G: Positron emission tomography using (18-F) fluorodeoxyglucose in brain tumors: A powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360-371.
8. Dose J, Avril N, Ziegler S, Bense S, Römer W, Weber W, Schwaiger M, Jänicke F, Graeff H: Stellenwert der Positronen-Emissions-Tomographie (PET) mit F-18 Fluordeoxyglukose (FDG) in der Diagnostik von Mammatumoren. Geburtsh Frauenheilk 1997, in press.
9. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, Phalen JJ, Sunderland JJ, Frick MP: Solitary pulmonary nodules: Detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-444.
10. Heywang SH, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W: MR imaging of the breast with Gd-DTPA: Use and limitations. Radiology 1989;171:95-103.
11. Huovinen R, Leskinen KS, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M: Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 1993;67:787-791.
12. Kubota K, Matsuzwana T, Amemiya A, Kondo M, Fujiwara T, Watanuki S, Ito M, Ido T: Imaging of breast cancer with (F-18) fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989;13:1097-1098.
13. Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, Ziegler S, Kruschke C, Arnold W, Schwaiger M: Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging of head and neck squamous-cell carcinomas. J Nucl Med 1995;36:1747-1757.
14. Okada J, K Yoshikawa, M Itami, K Imaseki, K Uno, J Itami, J Kuyama, A Mikata, N Arimizu: Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-329.
15. Römer W, Avril N, Dose J, Ziegler S, Kuhn W, Herz M, Jänicke F, Schwaiger M: Metabolische Charakterisierung von Ovarialtumoren mit der Positronen-Emissions-Tomographie und F-18-Fluordeoxyglukose. Fortschr Röntgenstr 1997;166:62-68.
16. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The C-14 deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
17. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN: 2-(Fluorine-18)-Fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation. Radiology 1995;195:339-344.
18. Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648.
19. Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA, Carter CL, Friedman MA: Neoadjuvant therapy in cancer treatment. Cancer 1993;72:3515-3524.
20. Wahl RL, Cody RL, Hutchins GD, Mudgett EE: Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179: 765-770.
21. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993;11:2101-2111.
22. Warburg O: The metabolism of tumors. London, Constable, 1930.